Skip to main content

Voiding & Outlet Pharmacotherapy

This section covers pharmacotherapy for male LUTS/BPH and drug approaches used or studied for urinary retention, stress incontinence, underactive bladder, and detrusor-sphincter dyssynergia. The classes have distinct targets: α₁ signaling in bladder-neck and prostatic smooth muscle, cholinergic receptors in the detrusor, prostatic 5α-reductase, and central or direct skeletal-muscle actions affecting the external sphincter and pelvic floor.[7][8][9]

For OAB / storage-phase therapy see Storage & OAB. For pelvic-floor hypertonicity in the context of neuropathic pelvic pain see Neuropathic & Pelvic Pain.

  • α-BlockersTamsulosin and related drugs for male LUTS/BPH, trial without catheter after BPH-related acute retention, and selected 5–10 mm distal ureteral stones, with safety counseling.[10][11]
  • 5α-Reductase InhibitorsFinasteride and dutasteride for an enlarged prostate, including their effect on PSA and the cancer-detection debate.
  • α-AgonistsMidodrine, pseudoephedrine and related drugs for ejaculatory problems, with their weak evidence for stress incontinence.
  • Cholinergic AgonistsBethanechol for nonobstructive retention; contraindicated in bladder-neck obstruction.[1] EAU 2026 strongly recommends against routine parasympathomimetics for underactive bladder.[2][3]
  • Skeletal Muscle RelaxantsBaclofen for neurologic spasticity and sphincter dysfunction; diazepam for high-tone pelvic-floor disorders; and cyclobenzaprine for short-term musculoskeletal spasm, with off-label pelvic-floor use and safety limits.[4][5][6]
  • DantroleneA muscle relaxant once used for sphincter dyssynergia after spinal cord injury, now largely historical because of liver toxicity.

References​

1. Amneal Pharmaceuticals LLC. "Bethanechol Chloride Tablets, USP: prescribing information." DailyMed. Rev. 05-2018-03. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=45285692-de51-413e-8a51-7fb792eccc81

2. European Association of Urology. "EAU Guidelines on the Management of Non-neurogenic Male LUTS: Disease Management." Uroweb. 2026. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management

3. European Association of Urology. "EAU Guidelines on Non-neurogenic Female LUTS: Disease Management." Uroweb. 2026. https://uroweb.org/guidelines/non-neurogenic-female-luts/chapter/disease-management

4. Tousignant A, Blais MA, Tu LM, Morin M, Ismail S. "A scoping review of the oral treatment options for the management of detrusor sphincter dyssynergia." Neurourol Urodyn. 2025;44(4):743-753. doi:10.1002/nau.25642

5. Flatow V, Uy-Kroh J, Carey ET, Ascher-Walsh C, Khalil S. "Skeletal muscle relaxants for the treatment of myofascial pelvic pain and high tone pelvic floor disorders." Curr Opin Obstet Gynecol. 2023;35(4):311-315. doi:10.1097/GCO.0000000000000894

6. RedPharm Drug Inc. "Cyclobenzaprine HCl Tablets, USP: prescribing information." DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee3f98d0-71bb-42d3-b863-5bf92adf6353&type=display

7. Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG. "5-alpha reductase inhibitors use in prostatic disease and beyond." Transl Androl Urol. 2023;12(3):487-496. doi:10.21037/tau-22-690

8. Advagen Pharma Ltd. "Baclofen oral solution: prescribing information." DailyMed. Revised April 2025. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75ab298b-b2a7-458f-accc-5bfc89b89a16

9. Par Health USA. "Dantrium (dantrolene sodium) capsules: prescribing information." DailyMed. Revised July 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57b4eec1-49e1-432c-95ae-0fe36e32d64b

10. Althunayan GS, Almuossa BM, Almulla MA, Alshazly H, Al-Hayani AM, Hetou K. "Efficacy and safety of α1-adrenergic receptor antagonists in managing acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials." Arch Ital Urol Androl. 2026;98(3):15967. doi:10.4081/aiua.2026.15967

11. Almaghthawi MM, Alotaibi EA, Alotaibi MS, et al. "Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025." Arab J Urol. 2026;24(1):1-14. doi:10.1080/20905998.2025.2532196